Havens Advisors’s AstraZeneca AZN Stock Holding History

Havens Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,000	Closed	-$497K	–	47
2021 Q1	$497K	Buy	+5,000	New	+$503K	0.44%	26

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Havens Advisors's AZN Position: Q3 2014 in Review

Havens Advisors sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 4,000 shares — an estimated $297K sold.

Havens Advisors first reported a position in AZN in Q2 2014 and held it in 1 quarter. The position peaked at $297K in Q2 2014. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

Havens Advisors reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
Havens Advisors sold 4,000 AstraZeneca shares in Q3 2014, an estimated $297K.
Havens Advisors first reported a position in AstraZeneca in Q2 2014 and held it in 1 quarter.
Havens Advisors's AstraZeneca position peaked at $297K in Q2 2014.
402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Havens Advisors's 13F filing for Q3 2014, filed 31 Oct 2014.